| Drug-Target Information | ||||||||
|---|---|---|---|---|---|---|---|---|
| Drug Name | Target Name | Drug Type | Target Type | Source | Drug MeSHID | Interaction Score | Drug Status | Target Action |
| amg 386 | angiopoietin-1 | NA | Clinical trial target | TTD , DGIDB | Neuralgia[MeSHID:D009437] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Malignant neoplasm of breast[MeSHID:D001943] Asthma[MeSHID:D001249] |
NA | phase 3 | unknown |
| amg 386 | angiopoietin-2 | NA | Clinical trial target | TTD , DGIDB | Neuralgia[MeSHID:D009437] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Malignant neoplasm of breast[MeSHID:D001943] Asthma[MeSHID:D001249] |
NA | phase 3 | unknown |
| amg 386 | neuronal acetylcholine receptor alpha-7 | NA | Successful target | TTD , DGIDB | Neuralgia[MeSHID:D009437] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Malignant neoplasm of breast[MeSHID:D001943] Asthma[MeSHID:D001249] |
NA | phase 3 | unknown |
| amg 386 | melanocortin receptor 4 | NA | Successful target | TTD , DGIDB | Neuralgia[MeSHID:D009437] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Malignant neoplasm of breast[MeSHID:D001943] Asthma[MeSHID:D001249] |
NA | phase 3 | unknown |
| amg 386 | tax transcriptionally-activated glycoprotein 1 | NA | Clinical trial target | TTD , DGIDB | Neuralgia[MeSHID:D009437] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Malignant neoplasm of breast[MeSHID:D001943] Asthma[MeSHID:D001249] |
NA | phase 3 | unknown |
| click here to return to the previous page | ||||||||